DermTech Inc at BTIG Virtual MedTech, Digital Health, Life Sciences, and Diagnostic Tools Conference Transcript
Welcome. I'm Sung Ji Nam, tools and diagnostics analyst at BTIG. It is my pleasure to introduce DermTech. Presenting for DermTech are John Dobak, President and CEO; and Kevin Sun, CFO. With that, I will turn it over to John for some introductory remarks.
Great. Thank you, Sung Ji, and thanks for everybody who participate in our session right now. DermTech is creating a new category of medicine we refer to as precision dermatology, and this category is enabled by our noninvasive skin genomics platform. What we're able to do is collect a skin sample noninvasively using an adhesive patch. And from the material collected on that patch, we can provide a variety of genomic analyses and provide very accurate diagnosis of skin conditions.
We're mostly focused in skin cancer, and our first product is the Pigmented Lesion Assay, which is a test for melanoma. The test is commercially available across
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |